Momelotinib Shows Promising JAK and ALK2 Inhabitation in Patients With Anemic Myelofibrosis: MOMENTUM Study It’s my pleasure today to discuss with you the results of the MOMENTUM study as presented at EHA 2022. The MOMENTUM study is an incredibly important study in the development of a drug called Momelotinib, a JAK inhibitor that differentiates itself … Continue reading Momelotinib a JAK inhibitor vs Danazol in Myelofibrosis